Montreal, QC H4Z 1E9
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees:
|Mr. Ferras Zalt||Chairman & Interim CEO||110.17k||N/A||1963|
|Ms. Kym No C.M.A., CPA||Corp. Controller & Interim CFO||134.01k||N/A||N/A|
|Mr. Guy Charette L.L.B., LL.B.||Legal Council||N/A||N/A||1954|
|Mr. Jeanne van Wyk||VP of Communications||N/A||N/A||N/A|
|Mr. Daniel Lubienietzky||VP of Corp. Devel.||N/A||N/A||N/A|
|Mr. Richard Widmann||EVP of Commercial||N/A||N/A||1968|
|Mr. Michael Kozub||Corp. Sec.||N/A||N/A||N/A|
Elixxer Ltd. operates as a cannabis investment firm in Canada, Australia, Italy, Jamaica, and Switzerland. It invests in cannabis related businesses, which are fully licensed for cultivation, production, and/or sale of medical and specialty cannabis and cannabis derived products in the pharmaceutical sector. The company was formerly known as LGC Capital Ltd. and changed its name to Elixxer Ltd. in August 2019. Elixxer Ltd. is based in Montreal, Canada.
Elixxer Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.